Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Virginia Kaklamani, MD, DSc; Kamel Abou Hussein, MD; Javier Cortés, MD, PhD; and Seth A. Wander, MD, PhD, discuss American Society of Clinical Oncology (ASCO) 2026 updates about data for oral selective estrogen receptor degraders (SERDs) to treat metastatic, HR-positive breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify approved and emerging oral SERDs for the management of HR+/HER2– breast cancer
• Assess emerging clinical trial and real-world evidence to gain practical insights into the appropriate use of oral SERD–based treatment strategies for patients with HR+/HER2– MBC
• Integrate clinical trial data, real-world evidence, and patient- and disease-specific factors to inform personalized treatment decisions for patients with HR+/HER2– MBC

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Stemline Therapeutics, Inc.

Chair:

Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio, MD Anderson Cancer Center
San Antonio, TX

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Daiichi Sankyo, Genentech, Gilead, Menarini, Pfizer; Speakers Bureau: AstraZeneca, Gilead

Faculty:

Kamel Abou Hussein, MD

Assistant Professor of Medicine
Cooper Medical School of Rowan University
MD Anderson Cancer Center at Cooper
Camden, NJ

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca; Speakers Bureau: Lilly

Javier Cortés, MD, PhD

Head of the International Breast Cancer Center
Barcelona, Spain
Director of IOB Institute of Oncology Madrid
Madrid, Spain

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Bioasis, BioInvent, Boehringer Ingelheim, Clovis Oncology, Daiichi Sankyo, Ellipses, GEMoaB, Gilead, HiberCell, Leuko, Menarini, Merck Sharp & Dohme, Roche, Seattle Genetics, Zyme; Speakers Bureau: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline; Grant/Research Funding: Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoff, Roche; Ownership Interests in Privately Held Companies: Leuko (relative), MAJ3 Capital SL; Employee/Owner: International Cancer Experts SL, MAJ3; Royalty or Patent Benefits: Pharmaceutical Combinations of a Pi3k Inhibitor and a Microtubule Destabilizing Agent—Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizald

Seth A. Wander, MD, PhD

Assistant Professor of Medicine
Harvard Medical School
Medical Oncologist
Massachusetts General Hospital
Boston, MA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Arvinas, AstraZeneca, Biovica, Boundless Bio, Celcuity, Delcath, Foundation Medicine, Genentech, Gilead, Halda Therapeutics, Hologic, Lilly, Novartis, Pfizer, Puma Biotechnology, Regor Therapeutics, Stemline/Menarini, Veracyte; Grant/Research Funding: Arvinas, Genentech, Lilly, Nuvation Bio, Pfizer, Phoenix Molecular Designs, Puma Biotechnology, Regor Therapeutics, Sermonix, Stemline/Menarini

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the latest data for oral SERDs, go to https://www.gotoper.com/courses/oncology-town-hall-updates-from-chicago-oral-serds-in-hrher2-metastatic-breast-cancerwhat-the-latest-data-really-tell-us

Release Date

July 15, 2026

Expiration Date

July 15, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.